Allarity Therapeutics (ALLR)

About Allarity Therapeutics (ALLR)

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.

Allarity Therapeutics News